Acadia Pharmaceuticals reported $40.99M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD 40.99M 42.62M Jun/2026
ALKERMES USD 120.06M 19.15M Sep/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
Biogen USD 450.8M 198.9M Jun/2026
BioMarin Pharmaceutical USD 54.32M 167.99M Sep/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Cara Therapeutics USD -2.39M 3.16M Mar/2025
Corcept Therapeutics USD 115.75M 73.59M Sep/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
Eisai JPY 25.94B 8.21B Sep/2026
Eli Lilly USD 9.46B 3.54B Sep/2026
Incyte USD 778.57M 410.6M Jun/2026
J&J USD 8.99B 721M Jun/2026
Moderna USD -687M 571M Jun/2026
Neurocrine Biosciences USD 375.3M 185.4M Sep/2026
Pfizer USD 6.36B 350M Sep/2026
Prothena USD -18.49M 44.46M Jun/2026
PTC Therapeutics USD 161.9M 99.92M Jun/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
Ultragenyx Pharmaceutical USD -61M 94M Jun/2026
Vanda Pharmaceuticals USD -8.31M 2.37M Dec/2024
Vertex Pharmaceuticals USD 888.6M 436.6M Sep/2026